FDA approves fourth product under National Priority Voucher program, higher dose semaglutide
Previous studies suggested that patients with T2D typically experience lower %WL with GLP-1RAs, including semaglutide 2.4 mg compared with those with normoglycemia 22
#17 Worked my way up from 2mg to 4 for a few months and now Ive been on 6 for the last few weeks, nothing noticable for me #18 I have no raised RHR at all on Reta, currently at 2mg every 5 days, which I will be bumping up to 3mg/week, since 2mg every 5 days equals to 2.8mg/week #20 Worked my way up from 2mg to 4 for a few months and now Ive been on 6 for the last few weeks, nothing noticable for me See below
Clinically, the importance of Ecust004 lies in its dual-targeting mechanism by serving both as a tubulin and steroid sulfatase inhibitor, which effectively induces G2/M cell cycle arrest and reverses EMT, a key driver of metastasis, by upregulating E-cadherin and downregulating transcription factors such as SLUG and ZEB1 (115)
